1. Home
  2. NOV vs BLCO Comparison

NOV vs BLCO Comparison

Compare NOV & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NOV Inc.

NOV

NOV Inc.

HOLD

Current Price

$17.94

Market Cap

5.7B

Sector

Industrials

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$17.28

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOV
BLCO
Founded
1862
1853
Country
United States
Canada
Employees
N/A
N/A
Industry
Metal Fabrications
Ophthalmic Goods
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7B
6.0B
IPO Year
1996
2022

Fundamental Metrics

Financial Performance
Metric
NOV
BLCO
Price
$17.94
$17.28
Analyst Decision
Hold
Hold
Analyst Count
14
14
Target Price
$16.71
$17.31
AVG Volume (30 Days)
3.9M
332.5K
Earning Date
02-04-2026
02-18-2026
Dividend Yield
1.67%
N/A
EPS Growth
N/A
N/A
EPS
1.00
N/A
Revenue
$8,775,000,000.00
$4,976,000,000.00
Revenue This Year
N/A
$8.06
Revenue Next Year
N/A
$5.79
P/E Ratio
$18.06
N/A
Revenue Growth
N/A
6.23
52 Week Low
$10.84
$10.45
52 Week High
$18.22
$18.14

Technical Indicators

Market Signals
Indicator
NOV
BLCO
Relative Strength Index (RSI) 66.43 56.07
Support Level $17.55 $17.18
Resistance Level $18.22 $17.86
Average True Range (ATR) 0.55 0.42
MACD 0.13 -0.02
Stochastic Oscillator 89.87 64.63

Price Performance

Historical Comparison
NOV
BLCO

About NOV NOV Inc.

NOV (formerly National Oilwell Varco) is a leading supplier of oil and gas drilling rig equipment and products, such as downhole tools, drill pipe, and well casing. The company operates on a global scale, with international markets contributing nearly two thirds of its annual revenue.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: